Relay Therapeutics’ Post

Meet Aris Perrou at the AE&T in London and discuss how PAIA Biotech GmbH can help you improve your early #developability screening efforts.👍 Great technology🚀 #antibodydiscovery #mAbs #antibodyengineering #innovation

In the fast-paced world of #ADCs (antibody-drug conjugates), where multi-billion dollar deals are the norm, what comes next? Our team (Patrick Flynn, Ph.D., Smruthi Suryaprakash, Dan Grossman, Val Panier, John Wu) has published a paper in #NRDD (Nature Review Drug Discovery) that examines the current ADC pipeline, categorizes technological innovations being explored, and assesses their potential in addressing current challenges and expanding the utility of ADCs. Check out the link below to read our insights and don't hesitate to reach out if you have any questions! https://lnkd.in/dN3yhYTs

Cybin has an exciting journey ahead with multiple key data readouts and clinical milestones expected in the coming months and next year across the pipeline. We look forward to sharing: - Complete Phase 2 CYB003 efficacy and safety data in MDD in Q4 2023 - Phase 1 data for deuterated DMT molecules, CYB004 and SPL028, in Q4 2023 -Additional Phase 2 data assessing 12-week durability for CYB003 in Q1 2024 Cybin CEO Doug Drysdale said, “Looking ahead, Cybin plans to run four clinical studies in 2024, reflecting the team’s strong execution on strategic priorities and commitment to accelerating our programs. We are in an exciting period of clinical development, and we look forward to sharing important data readouts across our pipeline of differentiated therapeutics." Learn more: https://lnkd.in/gk5AXa4u #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch #clinicalresearch #mentalhealthresearch #CybinInc #DrugDevelopment #Biotech #MentalHealth

In the fast-paced world of #ADCs (antibody-drug conjugates), where multi-billion dollar deals are the norm, what comes next? Our team (Patrick Flynn, Ph.D., Smruthi Suryaprakash, Dan Grossman, Val Panier, John Wu) has published a paper in #NRDD (Nature Review Drug Discovery) that examines the current ADC pipeline, categorizes technological innovations being explored, and assesses their potential in addressing current challenges and expanding the utility of ADCs. Check out the link below to read our insights and don't hesitate to reach out if you have any questions!

Today’s Q2 2023 financial results demonstrate strong advancements in our clinical and preclinical programs. For more on that and our business development efforts, listen to the recording: https://bit.ly/43XLPPX #GenomicMedicines #CellTherapy #GeneTherapy

📢 Important Announcement: Fresh Tracks Therapeutics After months of careful consideration, Fresh Tracks Therapeutics has made the difficult decision to dissolve its operations. The board of directors has unanimously approved a liquidation plan. 🏔️ Based in Colorado, Fresh Tracks Therapeutics, a medical device company, has been dedicated to pioneering medical solutions. However, the challenging decision to cease all clinical and preclinical research programs and the unfortunate necessity to lay off the majority of our personnel by the beginning of October has been made to responsibly manage the company's situation and ensure a smooth winding down process. #FreshTracksTherapeutics #medicalinnovation #companyupdate #liquidation #healthcareinnovation #medicalresearch #thankyou #innovationinmedicine

Don't miss Kim Frederix at today's congress of European Drug Discovery Innovation & Outsourcing Programme organized by Drug Discovery Innovation Programme (DDIP). Schedule a meeting now to discover how InnoSer can help you achieve breakthroughs on your preclinical drug discovery path! InnoSer is active in #DrugDevelopment pipelines, spanning from the early target validation until the late preclinical research phase. Learn more about how you can benefit from our capabilities here: https://lnkd.in/eciRBYbq #DDIP #DDIPEU

📈 We have witnessed a huge increase in the total number of preclinical ADC drugs over the past 3 years! Of the 804 ADCs currently in preclinical development, over 70% are classed as active, demonstrating evidence of continued development and instilling developers with confidence for future advancements. If you’re finding it challenging to keep up with this constantly evolving space, then our infographic is for you! Discover top targets and moiety formats, recent trends in the disease landscape, and a breakdown of the 330 payloads being used. Download it here: https://ter.li/1fd2ac 📄 #ADCs #Preclinical #HER2 #DrugDevelopment

As R&D teams in #Pharma and #BioTech drive innovation with new modalities and personalized medicines, #TechOps face the challenge of removing roadblocks to #Commercialization – production costs and turnaround times. Geoffrey Zassenhaus shares how we helped the CMC team of a leading biotech collaborate to redesign its production processes to reduce costs by a factor of 25 and time to patient by 50%. https://lnkd.in/eDXbbbhf

Kezar Life Sciences changes CEOs, lays off 41% of staff and halts preclinical R&D to extend cash runway https://lnkd.in/g_z6cq6D Kezar Life Sciences, a 2015 spinout from Amgen, is laying off 41% of its workforce and pausing all preclinical R&D in a bid to extend its cash runway into late 2026 and move select clinical [...]